Eco-label tags "Environmentalists" systems
In Europe four Shimadzu product series carry the eco-label representing the company's multi-levelled energy saving program. The GCMS-QP2010 Ultra and SE and the LC-20AP systems, as well as the brand-new GC-2025 and the TOC-L series feature the eco-label.
In Europe four Shimadzu product series carry the eco-label representing the company’s multi-levelled energy saving program. The GCMS-QP2010 Ultra and SE and the LC-20AP systems, as well as the brand-new GC-2025 and the TOC-L series feature the eco-label. It tags only the most energy efficient instruments which meet the highest environmental standards. Users profit from lower running and maintenance costs and less energy spending.
The eco-labelled systems save between 25 and 40% energy. Furthermore, materials consumption is lower, operational costs are less and the CO2 emissions have been reduced. More environmentalists systems are already in the production pipeline.
The GCMS-QP2010 Ultra features an eco-mode for stand-by operation allowing a lower total cost of ownership with less environmental stress. The GC-2025’s power consumption is reduced by 30% for programmed temperature analysis in comparison to other GC models. The energy consumption of the TOC-L series has been reduced by 36% (100 V) and 43% (200 V) in comparison with conventional Shimadzu models (assuming 8 hours operation/day × 5 days/week).
For more details please visit www.shimadzu.eu.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
